DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Neuropathic Pain” report has been added to ResearchAndMarkets.com’s
offering.
This Market Spotlight report covers the neuropathic pain market,
comprising key marketed and pipeline drugs, recent events and analyst
opinion, clinical trials, upcoming events, probability of success,
patent information, a 10-year disease prevalence forecast, and licensing
and asset acquisition deals, as well as presenting drug-specific revenue
forecasts
Key Takeaways
-
The report estimates that in 2017, there were 425.2 million prevalent
cases of neuropathic pain in adults aged 20 years and older worldwide,
and forecasts that number to increase to 476.2 million prevalent cases
by 2026. -
Asia is estimated to have had the largest number of prevalent cases in
2017, driven by population size, while having the lowest prevalence
proportion (98.1 million cases; 3.20%). -
The marketed drugs in the neuropathic pain space target sodium
channels, voltage-gated calcium channels, and transient receptor
potential vanilloid receptor 1. These drugs are administered via the
oral route, except for Qutenza, which is available as a topical
formulation. -
The majority of industry-sponsored drugs in active clinical
development for neuropathic pain are in Phase I. Therapies in
development for neuropathic pain focus on a wide variety of targets.
The majority of pipeline drugs in early- and mid-stage development are
administered orally, with the remainder being intravenous,
intramuscular, intraarticular, intrathecal, intradermal, subcutaneous,
and topical formulations. -
A new partnership for V158866 is the only high-impact upcoming event
in the neuropathic pain space. The overall likelihood of approval of a
Phase I neuropathic pain asset is 0.9%, and the average probability a
drug advances from Phase III is 33.3%. Drugs, on average, take 8.8
years from Phase I to approval, compared to 9.6 years in the overall
neurology space. -
There have been 25 licensing and asset acquisition deals involving
neuropathic pain drugs during 2014-19, eight of which occurred in
2015. The exclusive licensing agreement in 2015 between Depomed and
Janssen for the acquisition of the US rights to Nucynta for $1.05bn
was the largest deal during the period. -
The distribution of clinical trials across Phase I-IV indicates that
the majority of trials have been in the early and mid-phases of
development, with 69% of trials in Phase I-II, and only 31% in Phase
III-IV. -
The US has a substantial lead in the number of neuropathic pain
clinical trials globally. The UK leads the major EU markets, while
Japan has the top spot in Asia. -
Clinical trial activity in the neuropathic pain space is dominated by
completed trials. Pfizer has the highest number of completed clinical
trials for neuropathic pain, with 230 trials. -
Pfizer leads industry sponsors with by far the highest number of
clinical trials for neuropathic pain, followed by Allergan.
Key Topics Covered:
OVERVIEW
KEY TAKEAWAYS
DISEASE BACKGROUND
Subtypes
TREATMENT
Antidepressants
Antiepileptics
Cannabinoids
Opioids
Topical or focal therapies
EPIDEMIOLOGY
Limitations of neuropathic pain prevalence estimates
MARKETED DRUGS
PIPELINE DRUGS
RECENT EVENTS AND ANALYST OPINION
VX-150 for Neuropathic Pain (December 18, 2018)
CNTX-4975 for Neuropathic Pain (November 07, 2017)
KEY UPCOMING EVENTS
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
PARENT PATENTS
REVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
BIBLIOGRAPHY
For more information about this report visit https://www.researchandmarkets.com/r/ny3g4l
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs , Analgesics